Clinical Trial: Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.

Brief Summary: The purpose of this study is to determine the effects of AT1001 on the safety of agalsidase, and the effects of agalsidase on the safety of AT1001.

Detailed Summary:
Sponsor: Amicus Therapeutics

Current Primary Outcome: Plasma pharmacokinetics [ Time Frame: Over 24-hour period after dosing ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Amicus Therapeutics

Dates:
Date Received: September 7, 2010
Date Started: February 2011
Date Completion:
Last Updated: December 19, 2013
Last Verified: December 2013